H. Tilly

474 total citations
7 papers, 229 citations indexed

About

H. Tilly is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, H. Tilly has authored 7 papers receiving a total of 229 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in H. Tilly's work include Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (4 papers) and CAR-T cell therapy research (2 papers). H. Tilly is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (4 papers) and CAR-T cell therapy research (2 papers). H. Tilly collaborates with scholars based in France, United States and Switzerland. H. Tilly's co-authors include Corinne Haïoun, Gilles Salles, Olivier Casasnovas, Nicolas Mounier, Catherine Sebban, Serge Bologna, Richard Delarue, Pauline Beaussart, Taoufik El Gnaoui and Anne Sonet and has published in prestigious journals such as Annals of Oncology, Haematologica and Blood Advances.

In The Last Decade

H. Tilly

7 papers receiving 226 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Tilly France 4 204 160 76 54 20 7 229
Jesús Alarcón Spain 7 118 0.6× 105 0.7× 61 0.8× 31 0.6× 6 0.3× 14 210
Antonella Anastasia Italy 10 216 1.1× 161 1.0× 78 1.0× 92 1.7× 17 0.8× 21 284
T Anderson United States 7 124 0.6× 156 1.0× 60 0.8× 35 0.6× 36 1.8× 8 243
Jesse Shustik Canada 5 114 0.6× 78 0.5× 50 0.7× 27 0.5× 16 0.8× 11 142
Chiara Lobetti‐Bodoni Switzerland 8 159 0.8× 106 0.7× 73 1.0× 40 0.7× 8 0.4× 12 189
Georg Lenz Germany 2 240 1.2× 184 1.1× 85 1.1× 33 0.6× 23 1.1× 2 265
Olaf Determann Germany 4 195 1.0× 130 0.8× 82 1.1× 18 0.3× 5 0.3× 4 214
Julie Lisano United States 6 197 1.0× 174 1.1× 43 0.6× 90 1.7× 22 1.1× 16 255
Paolo Caimi United States 7 228 1.1× 193 1.2× 65 0.9× 113 2.1× 14 0.7× 9 265
Henriette W Berenschot Netherlands 6 126 0.6× 103 0.6× 62 0.8× 20 0.4× 19 0.9× 11 164

Countries citing papers authored by H. Tilly

Since Specialization
Citations

This map shows the geographic impact of H. Tilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Tilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Tilly more than expected).

Fields of papers citing papers by H. Tilly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Tilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Tilly. The network helps show where H. Tilly may publish in the future.

Co-authorship network of co-authors of H. Tilly

This figure shows the co-authorship network connecting the top 25 collaborators of H. Tilly. A scholar is included among the top collaborators of H. Tilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Tilly. H. Tilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Hu, Bei, Patrick M. Reagan, Laurie H. Sehn, et al.. (2025). Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Advances. 9(10). 2489–2499. 3 indexed citations
2.
Topp, Max S., Monica Tani, Michael Dickinson, et al.. (2025). 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY. Hematological Oncology. 43(S3). 1 indexed citations
3.
4.
5.
Colombat, P, Nicole Brousse, Gilles Salles, et al.. (2012). Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Annals of Oncology. 23(9). 2380–2385. 36 indexed citations
6.
Ketterer, Nicolas, Catherine Thiéblemont, Christophe Fermé, et al.. (2012). Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Annals of Oncology. 24(4). 1032–1037. 21 indexed citations
7.
Fitoussi, Olivier, Karim Belhadj, Nicolas Mounier, et al.. (2011). Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 96(8). 1136–1143. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jesús Alarcón Breakdown of academic impact, for papers by Antonella Anastasia Breakdown of academic impact, for papers by T Anderson Breakdown of academic impact, for papers by Jesse Shustik Breakdown of academic impact, for papers by Chiara Lobetti‐Bodoni Breakdown of academic impact, for papers by Georg Lenz Breakdown of academic impact, for papers by Olaf Determann Breakdown of academic impact, for papers by Julie Lisano Breakdown of academic impact, for papers by Paolo Caimi Breakdown of academic impact, for papers by Henriette W Berenschot
Rankless by CCL
2026